Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.33 | -0.75% | -0.01 |
MRNS closed down 0.75 percent on Wednesday, May 15, 2024, on 45 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 22
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -0.75% | |
NR7-2 | Range Contraction | -0.75% | |
Narrow Range Bar | Range Contraction | -0.75% | |
Oversold Stochastic | Weakness | -0.75% | |
20 DMA Resistance | Bearish | -1.48% | |
NR7 | Range Contraction | -1.48% | |
Narrow Range Bar | Range Contraction | -1.48% |
Alert | Time |
---|---|
20 DMA Resistance | about 14 hours ago |
10 DMA Resistance | about 14 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
Up 5% | about 14 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/22/2024
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.26 |
52 Week Low | 1.11 |
Average Volume | 2,416,774 |
200-Day Moving Average | 7.52 |
50-Day Moving Average | 5.37 |
20-Day Moving Average | 1.42 |
10-Day Moving Average | 1.42 |
Average True Range | 0.31 |
RSI (14) | 18.03 |
ADX | 64.3 |
+DI | 10.90 |
-DI | 41.90 |
Chandelier Exit (Long, 3 ATRs) | 0.85 |
Chandelier Exit (Short, 3 ATRs) | 2.03 |
Upper Bollinger Bands | 1.54 |
Lower Bollinger Band | 1.30 |
Percent B (%b) | 0.12 |
BandWidth | 16.96 |
MACD Line | -1.10 |
MACD Signal Line | -1.36 |
MACD Histogram | 0.2611 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.51 | ||||
Resistance 3 (R3) | 1.53 | 1.49 | 1.48 | ||
Resistance 2 (R2) | 1.49 | 1.44 | 1.48 | 1.47 | |
Resistance 1 (R1) | 1.41 | 1.42 | 1.39 | 1.39 | 1.46 |
Pivot Point | 1.37 | 1.37 | 1.36 | 1.36 | 1.37 |
Support 1 (S1) | 1.29 | 1.32 | 1.27 | 1.27 | 1.20 |
Support 2 (S2) | 1.25 | 1.30 | 1.24 | 1.19 | |
Support 3 (S3) | 1.17 | 1.25 | 1.18 | ||
Support 4 (S4) | 1.15 |